Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS Kidney Transplant Drug Approved | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

BMS Kidney Transplant Drug Approved

Bristol-Myers Squibb received approval from the FDA for Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb received approval from the FDA for Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant.

Nulojix is a selective T-cell costimulation blocker. The drug helps to prevent organ rejection after a kidney transplant. Without immunosuppression, the body can reject a transplanted organ because the immune system recognizes the new organ as foreign (transplant rejection).

Nulojix was evaluated in two open-label, randomized, multicenter, controlled Phase III studies that enrolled more than 1,200 patients and compared two dose regimens of Nulojix with another immunosuppressant, cyclosporine. These trials demonstrated that the recommended Nulojix regimen is safe and effective for the prevention of acute organ rejection.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters